Elicio Therapeutics (ELTX) Consolidated Net Income (2020 - 2026)

Elicio Therapeutics (ELTX) has 7 years of Consolidated Net Income data on file, last reported at -$10.9 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income fell 1.4% year-over-year to -$10.9 million; the trailing twelve-month figure through Mar 2026 stood at -$38.4 million (up 15.64% YoY), and the FY2025 full-year result was -$38.8 million, up 14.51% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$10.9 million, down from -$9.2 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at -$6.0 million in Q4 2022 and bottomed at -$14.5 million in Q1 2022.
• The 5-year median for Consolidated Net Income is -$10.1 million (2025), against an average of -$9.7 million.
• Peak annual rise in Consolidated Net Income reached 59.99% in 2022, while the deepest fall reached 140.99% in 2022.
• A 5-year view of Consolidated Net Income shows it stood at -$6.0 million in 2022, then slumped by 55.37% to -$9.3 million in 2023, then sank by 47.12% to -$13.7 million in 2024, then surged by 33.05% to -$9.2 million in 2025, then declined by 18.23% to -$10.9 million in 2026.
• The last three Consolidated Net Income figures came in at -$10.9 million (Q1 2026), -$9.2 million (Q4 2025), and -$8.3 million (Q3 2025), per Business Quant data.

Peer Comparison